Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and OrganiGram Holdings (OGI)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Exelixis (EXEL – Research Report) and OrganiGram Holdings (OGI – Research Report) with bullish sentiments.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Exelixis (EXEL)
TD Cowen analyst Yaron Werber maintained a Buy rating on Exelixis today and set a price target of $51.00. The company’s shares closed last Tuesday at $42.98.
According to TipRanks.com, Werber is a 5-star analyst with an average return of
Currently, the analyst consensus on Exelixis is a Moderate Buy with an average price target of $46.89, which is a 6.6% upside from current levels. In a report released today, William Blair also maintained a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
OrganiGram Holdings (OGI)
In a report released yesterday, Neal Gilmer from Haywood maintained a Buy rating on OrganiGram Holdings, with a price target of C$3.25. The company’s shares closed last Tuesday at $1.39.
According to TipRanks.com, Gilmer is a 1-star analyst with an average return of
OrganiGram Holdings has an analyst consensus of Strong Buy, with a price target consensus of $2.52, a 58.5% upside from current levels. In a report issued on January 27, Canaccord Genuity also initiated coverage with a Buy rating on the stock with a C$3.00 price target.
